These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1302 related articles for article (PubMed ID: 33983545)

  • 1. Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency.
    Kinoshita H; Durkee-Shock J; Jensen-Wachspress M; Kankate VV; Lang H; Lazarski CA; Keswani A; Webber KC; Montgomery-Recht K; Walkiewicz M; Notarangelo LD; Burbelo PD; Fuss I; Cohen JI; Bollard CM; Keller MD
    J Clin Immunol; 2021 Aug; 41(6):1146-1153. PubMed ID: 33983545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity.
    van Leeuwen LPM; GeurtsvanKessel CH; Ellerbroek PM; de Bree GJ; Potjewijd J; Rutgers A; Jolink H; van de Veerdonk F; van Gorp ECM; de Wilt F; Bogers S; Gommers L; Geers D; Bruns AHW; Leavis HL; van Haga JW; Lemkes BA; van der Veen A; de Kruijf-Bazen SFJ; van Paassen P; de Leeuw K; van de Ven AAJM; Verbeek-Menken PH; van Wengen A; Arend SM; Ruten-Budde AJ; van der Ent MW; van Hagen PM; Sanders RW; Grobben M; van der Straten K; Burger JA; Poniman M; Nierkens S; van Gils MJ; de Vries RD; Dalm VASH
    J Allergy Clin Immunol; 2022 Jun; 149(6):1949-1957. PubMed ID: 35421449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity.
    Steiner S; Schwarz T; Corman VM; Gebert L; Kleinschmidt MC; Wald A; Gläser S; Kruse JM; Zickler D; Peric A; Meisel C; Meyer T; Staudacher OL; Wittke K; Kedor C; Bauer S; Besher NA; Kalus U; Pruß A; Drosten C; Volk HD; Scheibenbogen C; Hanitsch LG
    Front Immunol; 2022; 13():840126. PubMed ID: 35359967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency.
    Arroyo-Sánchez D; Cabrera-Marante O; Laguna-Goya R; Almendro-Vázquez P; Carretero O; Gil-Etayo FJ; Suàrez-Fernández P; Pérez-Romero P; Rodríguez de Frías E; Serrano A; Allende LM; Pleguezuelo D; Paz-Artal E
    J Clin Immunol; 2022 Feb; 42(2):240-252. PubMed ID: 34787773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Immune Response to SARS-CoV-2 Vaccination: Insights Learned From Adult Patients With Common Variable Immune Deficiency.
    Quinti I; Locatelli F; Carsetti R
    Front Immunol; 2021; 12():815404. PubMed ID: 35126372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of SARS-CoV-2 Immunity in Convalescent Children and Adolescents.
    Tsang HW; Chua GT; To KKW; Wong JSC; Tu W; Kwok JSY; Wong WHS; Wang X; Zhang Y; Rosa Duque JS; Chan GCF; Chu WK; Pang CP; Tam PKH; Lau YL; Wong ICK; Leung WH; Yuen KY; Kwan MYW; Ip P
    Front Immunol; 2021; 12():797919. PubMed ID: 34975908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innate and adaptive immune responses to SARS-CoV-2 in humans: relevance to acquired immunity and vaccine responses.
    Jordan SC
    Clin Exp Immunol; 2021 Jun; 204(3):310-320. PubMed ID: 33534923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV.
    Alrubayyi A; Gea-Mallorquí E; Touizer E; Hameiri-Bowen D; Kopycinski J; Charlton B; Fisher-Pearson N; Muir L; Rosa A; Roustan C; Earl C; Cherepanov P; Pellegrino P; Waters L; Burns F; Kinloch S; Dong T; Dorrell L; Rowland-Jones S; McCoy LE; Peppa D
    Nat Commun; 2021 Oct; 12(1):5839. PubMed ID: 34611163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
    Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
    Front Immunol; 2021; 12():726960. PubMed ID: 34671348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Widely heterogeneous humoral and cellular immunity after mild SARS-CoV-2 infection in a homogeneous population of healthy young men.
    Le Bert N; Chia WN; Wan WY; Teo AKJ; Chong SZ; Tan N; Tan DSC; Chia A; Tan IB; Kunasegaran K; Chua QX; Abdad MY; Ng ASH; Vasoo S; Ang JX; Lee MS; Sun L; Fang J; Zhu F; Cook AR; Aw TC; Huang J; Tam C; Lee FS; Clapham H; Goh EJ; Peou MSS; Tan SP; Ong SK; Wang LF; Bertoletti A; Hsu LY; Ong BC
    Emerg Microbes Infect; 2021 Dec; 10(1):2141-2150. PubMed ID: 34709140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay.
    Brand I; Gilberg L; Bruger J; Garí M; Wieser A; Eser TM; Frese J; Ahmed MIM; Rubio-Acero R; Guggenbuehl Noller JM; Castelletti N; Diekmannshemke J; Thiesbrummel S; Huynh D; Winter S; Kroidl I; Fuchs C; Hoelscher M; Roider J; Kobold S; Pritsch M; Geldmacher C
    Front Immunol; 2021; 12():688436. PubMed ID: 34093595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigen-Specific CD4
    Sauerwein KMT; Geier CB; Stemberger RF; Akyaman H; Illes P; Fischer MB; Eibl MM; Walter JE; Wolf HM
    Front Immunol; 2022; 13():827048. PubMed ID: 35237272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HCoV- and SARS-CoV-2 Cross-Reactive T Cells in CVID Patients.
    Steiner S; Sotzny F; Bauer S; Na IK; Schmueck-Henneresse M; Corman VM; Schwarz T; Drosten C; Wendering DJ; Behrends U; Volk HD; Scheibenbogen C; Hanitsch LG
    Front Immunol; 2020; 11():607918. PubMed ID: 33424856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Robust and Persistent B- and T-Cell Responses after COVID-19 in Immunocompetent and Solid Organ Transplant Recipient Patients.
    Zavaglio F; Frangipane V; Morosini M; Gabanti E; Zelini P; Sammartino JC; Ferrari A; Gregorini M; Rampino T; Asti A; Seminari E; Di Matteo A; Cattadori B; Pellegrini C; Tonello S; Mallela VR; Minisini R; Rizzi M; Sainaghi PP; Meloni F; Lilleri D; Baldanti F
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients.
    Lafon E; Diem G; Witting C; Zaderer V; Bellmann-Weiler RM; Reindl M; Bauer A; Griesmacher A; Fux V; Hoermann G; Miller C; Zabernigg A; Wöll E; Wilflingseder D; Lass-Flörl C; Posch W
    Front Immunol; 2021; 12():684014. PubMed ID: 34194438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.
    Rosati M; Terpos E; Ntanasis-Stathopoulos I; Agarwal M; Bear J; Burns R; Hu X; Korompoki E; Donohue D; Venzon DJ; Dimopoulos MA; Pavlakis GN; Felber BK
    Front Immunol; 2021; 12():793953. PubMed ID: 34899762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2-Specific Antibody and T Cell Response Kinetics According to Symptom Severity.
    Kim JY; Kwon JS; Bae S; Cha HH; Lim JS; Kim MC; Chung JW; Park SY; Lee MJ; Kim BN; Jung J; Kim MJ; Shin EC; Kim SH
    Am J Trop Med Hyg; 2021 Jun; 105(2):395-400. PubMed ID: 34143752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Common Variable Immunodeficiency Disorders as a Model for Assessing COVID-19 Vaccine Responses in Immunocompromised Patients.
    Ameratunga R; Woon ST; Steele R; Lehnert K; Leung E; Edwards ESJ; Brooks AES
    Front Immunol; 2021; 12():798389. PubMed ID: 35116031
    [No Abstract]   [Full Text] [Related]  

  • 20. The Magnitude and Functionality of SARS-CoV-2 Reactive Cellular and Humoral Immunity in Transplant Population Is Similar to the General Population Despite Immunosuppression.
    Thieme CJ; Anft M; Paniskaki K; Blazquez-Navarro A; Doevelaar A; Seibert FS; Hoelzer B; Justine Konik M; Meister TL; Pfaender S; Steinmann E; Moritz Berger M; Brenner T; Kölsch U; Dolff S; Roch T; Witzke O; Schenker P; Viebahn R; Stervbo U; Westhoff TH; Babel N
    Transplantation; 2021 Oct; 105(10):2156-2164. PubMed ID: 33988334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 66.